---
title: "checkmate_577"
date: "2024-07-14"
tags:
  - building
---

> [!NOTE]
> ðŸŒ± created from: [[gastric cancer]]

# checkmate_577

- Design: Phase 3 randomized, double-blind, placebo-controlled trial
- Number of patients: 794 (532 received nivolumab, 262 received placebo)
- Patients characteristics: Adults with resected (R0) stage II or III esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy
- Agent: Nivolumab at a dose of 240 mg every 2 weeks for 16 weeks, followed by nivolumab at a dose of 480 mg every 4 weeks
- Treatment line: Adjuvant therapy
- Trial Acronym: CheckMate 577, ClinicalTrials.gov number NCT02743494
- Comparison of efficacy in one markdown table:
  - Median disease-free survival: 22.4 months with nivolumab vs 11.0 months with placebo
  - Hazard ratio for disease recurrence or death: 0.69
- Highlight of toxicity: Grade 3 or 4 adverse events related to the active drug occurred in 13% of patients in the nivolumab group vs 6% in the placebo group
- One line summary: Nivolumab adjuvant therapy significantly improved disease-free survival in patients with resected esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy.

### References

> [Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer | New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa2032125)
